person · Reporting owner
O'Brien Anthony Stephen
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.EVFM · Entity 8607 | Director | May 04, 2022 | May 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date May 04, 2022 · Filed May 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2032-05-04 | Direct | 6,000 |
Reported balance
After 2022-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-04 · Grant · Acquired 6,000 · Balance 6,000 F1: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022. F2: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Mr. O'Brien's board and committee services. |
Filing footnotes · ownership attribution and instrument terms
F1: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022.
F2: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Mr. O'Brien's board and committee services.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2022 Filed May 6, 2022 20:10 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001618835-22-000107 · wf-form4_165186782403107.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2032-05-04 F1 · derivative.exercise_price: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022. F1 · shares: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on May 5, 2022. F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 4, 2022. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 20:13 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 8,140 | $1.31 | $10,663.40 |
DisclosureSEC source: 0001618835-21-000153 · wf-form4_162370161055578.xml · nonDerivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,140 Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:14 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock · Derivative | 90,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001618835-21-000109 · wf-form4_162093682127478.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2021. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:40 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock · Derivative | 50,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001618835-20-000137 · wf-form4_158940241739274.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 12, 2020. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:02 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock · Derivative | 50,000 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001618835-19-000106 · wf-form4_155985135614038.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of June 5, 2019. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
| July 24, 2018 Filed Jul 27, 2018 20:27 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock · Derivative | 12,875 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001618835-18-000052 · wf-form4_153272320631529.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 Underlying: Common Stock · 12,875 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:18 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 24,691 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019705 · doc4.xml · derivative · entry 1 O'Brien Anthony Stephen · CIK 0001726732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,691 Underlying: Common Stock · 24,691 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Mr. O'Brien's board and committee services. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.